ROCKWELL MEDICAL, INC. Foreign Income Tax Expense (Benefit), Continuing Operations
ROCKWELL MEDICAL, INC. (RMTI) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-17.
Discontinued › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2020-03-17
- ROCKWELL MEDICAL, INC. foreign income tax expense (benefit), continuing operations for fiscal 2019 was $0.00.
- ROCKWELL MEDICAL, INC. foreign income tax expense (benefit), continuing operations for fiscal 2018 was $0.00.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-17 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B |